Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eleonor is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, which represents the current active matter for the company's intellectual property. This action is located within 1 distinct art unit, indicating that the technology being patented falls under a specific and focused classification at the patent office.
The prosecution is handled by 1 distinct examiner, AL-AWADI, DANAH J, who is also the busiest examiner with 1 pending action. This concentration of the portfolio's active matters under a single examiner means that the prosecution outcome is currently dependent on a single set of examiner perspectives. This allows the applicant to focus their legal strategy on the specific requirements and prior art interpretations of this individual.
With the busiest examiner pending count of 1 reflecting the total pending office actions, the portfolio's current prosecution is highly centralized. In the Biotechnology & Pharmaceuticals field, where technical details are paramount, this centralization can simplify the path to allowance if the examiner's concerns are met. Practitioners should focus on the specific requirements of the single pending action to advance the company's patent objectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AL-AWADI, DANAH J | 1 | 54.6% | +13.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918866 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | AL-AWADI, DANAH J | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17918866 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | AL-AWADI, DANAH J | 1615 | §103§112DP | Non-Final OA | — | Pending | Oct 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEleonor has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Danah J Al-Awadi has the most, with 1 of Eleonor's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.